Pemetrexed Plus Bevacizumab in Non Small Cell Lung Cancer

Sponsor
Hellenic Oncology Research Group
Study ID
NCT00741221
Phase
PHASE2
Status
Completed

Conditions

  • Non-small-cell Lung Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Pemetrexed — DRUG
    Pemetrexed (IV) 500 mg/m2 on day 1 every 3 weeks for 6 cycles
  • Bevacizumab — DRUG
    Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 6 cycles After the end of the 6 cycles Bevacizumab will be administered alone at the dose of 15 mgr/Kgr (IV) every 3 weeks until disease progression

Study Details

This trial will evaluate the efficacy and safety of pemetrexed and bevacizumab combination in patients with pretreated, advanced non small cell lung cancer (NSCLC).

Key Dates

First listed
Aug 26, 2008
Start date
Jun 30, 2008
Status verified
Oct 2016
Primary completion
Oct 31, 2016
Completion
Oct 31, 2016

Study Design

Enrollment
50 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: 1
    Pemetrexed/Bevacizumab

Primary Outcome Measure

Progression Free Survival [ Time Frame: 1 year ]

Related Studies